Rituximab-abbs (Truxima)

Monoclonal antibody

Biosimilar of Rituximab

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
US
  • Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) TRUXIMA, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
    Outside this platform's coverage
  • Pemphigus Vulgaris (PV) TRUXIMA is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.Outside this platform's coverage
  • Non-Hodgkin's Lymphoma (NHL)
Product first approved 2018FDA label
EU
  • Truxima: NHL, CLL, rheumatoid arthritis, GPA/MPA
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (3)
Rheumatoid Arthritis
Other / comorbidity
NCT02260804 · Celltrion
2015-11-09 – 2019-09-04 · Follicular Lymphoma
What this study did
NCT02162771 · Celltrion
2014-07-14 – 2018-12-29 · Lymphoma, Follicular
What this study did
Phase 1 (1)
Rheumatoid Arthritis
NCT01873443 · Celltrion
2013-05 – 2014-10 · Rheumatoid Arthritis
What this study did
Phase 4 (1)
Non-Hodgkin Lymphoma
NCT05191225 · Laida Cuevas Palomares
2021-09-28 – 2022-12 · Non-Hodgkin's Lymphoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Chronic Lymphocytic Leukemia
NCT05624554 · Merck Sharp & Dohme LLC
2023-03-16 – 2031-03-17 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rituximab-Abbs (Truxima): this drugApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
Ocrelizumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ocrevus Zunovo
Approved(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Ofatumumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
ABP 692
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BCD-281
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
CT-P53
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Divozilimab (Ivlizi)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Obinutuzumab Beta (Bejescin)
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.